Site icon OncologyTube

Progression on Sotorasib with KRAS+ NSCLC – 2022 Program: Targeted Therapies Forum

The landscape of treating KRAS+ NSCLC (Non-Small Cell Lung Cancer) is evolving, and understanding how to approach patient care after progression on Sotorasib is vital. In this specialized segment of the 2022 Targeted Therapies Forum, Dr. Jia Luo provides an in-depth examination of therapeutic options for patients who have progressed on Sotorasib.

This session is brought to you by our esteemed sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, who enable us to offer invaluable insights to the medical community.

For further information on this topic and other related fields in oncology, please visit cancerGRACE.org. To engage with experts, share experiences, and learn from peers, join the conversation at https://cancergrace.org/forum.

 

Exit mobile version